The field of psychedelic medicine has gained significant popularity over the past two to three years, with attention focused on uses for behavioral health disorders and even well-being.
Join us Wednesday, April 26, at 2 PM ET to review the use of psychedelic substances and how they impact the brain and behavior. Specifically, we will discuss psilocybin (a.k.a. "magic mushrooms"), MDMA, and ketamine as new research shows positive impacts on various mental health and substance use disorders.
Additionally, we will discuss current regulatory issues and challenges from the perspective of what this means for practicing clinicians. Since we expect the therapeutic psychedelics industry to grow from $3.6 billion in 2021 to $8.3 billion in 2028, will psychedelics become mainstream in behavioral health?
By attending, you’ll learn:
Vicki Ittel, PhD, MBA is the Director of Behavioral Health Solutions for Relias. In that role, she works with payers, providers, professional trade organizations, and government entities to design and apply digital analytical solutions that improve patient outcomes and create systemic change. Prior to joining Relias, Ittel held C-level positions at several national healthplans and formed several companies providing Medication Assisted Treatment to individuals with opioid use disorder. Ittel is passionate and committed to using innovative technological applications in healthcare transformation.